Document:

EX-10.6

 Exhibit 10.6 

RANI THERAPEUTICS, LLC 

2016 EQUITY INCENTIVE PLAN 

1. Purposes of the Plan. The purposes of this Equity Incentive Plan is to
attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Managers, Consultants and other individuals who provide services to or for the benefit of the Company, as determined by
the Administrator, and to promote the success of the Company’s business. The Plan permits the grant of Options, Profits Interests and Restricted Common Units. 

2. Definitions. As used herein, the following definitions will apply: 

(a) “Administrator” means the Board or any of its Committees as will be administering the Plan, in accordance with
Section 4 hereof. 
 (b) “Applicable Laws” means the requirements relating to the administration of equity-based
awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, and the applicable laws of any foreign country or jurisdiction where Awards are granted under the Plan. 

(c) “Award” means, individually or collectively, a grant under the Plan of Options, Profits Interests or Restricted Common
Units. 
 (d) “Award Agreement” a written or electronic agreement setting forth the terms and provisions applicable to each
Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan. 
 (e) “Board” means
the Board of Managers of the Company, as specified in the Operating Agreement. 
 (f) “Code” means the Internal Revenue
Code of 1986, as amended. Any reference to a Section of the Code herein will be a reference to any successor or amended Section of the Code. 

(g) “Committee” means a committee appointed by the Board in accordance with Section 4 hereof. 

(h) “Common Unit” means a Common Unit (as defined in the Operating Agreement) in the Company, or in the event of a Trigger
Event, means a share of common stock of the resulting corporation. 
 (i) “Company” means Rani Therapeutics, LLC, a
California limited liability company. 
 (j) “Consultant” means any person who is engaged by the Company or a Subsidiary to
render consulting or advisory services. 

 (k) “Disability” means total and permanent disability as defined in
Section 22(e)(3) of the Code. 
 (l) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(m) “Exchange Program” means a program under which (i) outstanding Options are surrendered or cancelled in exchange for
Options (which may have lower or higher exercise prices and different terms), awards of a different type, and/or cash, (ii) Optionees would have the opportunity to transfer any outstanding Options to a financial institution or other person or
entity selected by the Administrator, and/or (iii) the exercise price of an outstanding Option is reduced or increased. The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion. 

(n) “Fair Market Value” means, as of any date, the value of Units determined in good faith by the Administrator. 

(o) “Manager” will have the same meaning as defined in the Operating Agreement. 

(p) “Member” will have the same meaning as defined in the Operating Agreement. 

(q) “Operating Agreement” means the Second Amended and Restated Limited Liability Company Agreement of the Company, effective
as of May 21, 2015, as amended from time to time. Any reference to a Section of the Operating Agreement herein will be a reference to any successor or amended Section of the Operating Agreement. 

(r) “Option” means an option to purchase Common Units granted pursuant to the Plan. 

(s) “Option Agreement” means a written or electronic agreement between the Company and a Participant evidencing the terms and
conditions of an individual Option grant. The Option Agreement is subject to the terms and conditions of the Plan. 
 (t)
“Parent” means any entity in an unbroken chain of entities ending with the Company, if each of the entities other than the Company owns shares, or ownership interests possessing 50% or more of the total combined voting power of all
classes of shares or ownership interests in one of the other entities in such chain. 
 (u) “Participant” means the holder
of an outstanding Award. 
 (v) “Person” will have the same meaning as defined in the Operating Agreement. 

(w) “Plan” means this 2016 Equity Incentive Plan. 

(x) “Profits Interests” means a grant of Common Units pursuant to the Plan with a Profits Interest Threshold Amount fixed on
the date of issuance in accordance with the Operating Agreement that is intended to qualify as a partnership profits interest for U.S. Federal Income tax purposes. 

  
 -2- 

 (y) “Profits Interest Threshold Amount” has the meaning set forth in the
Operating Agreement. 
 (z) “Restricted Common Unit” means a grant of a Common Unit issued pursuant to a Restricted Unit
Award Agreement pursuant to the Plan. 
 (aa) “Restricted Unit Award Agreement” means a written or electronic agreement
between the Company and a Participant evidencing the terms and conditions of an individual Restricted Unit. The Restricted Unit Award Agreement is subject to the terms and conditions of the Plan. 

(bb) “Section 409A” means Section 409A of the Code, and the final regulations and any other guidance
issued thereunder or any state law equivalent. 
 (cc) “Securities Act” means the Securities Act of 1933, as amended. 

(dd) “Service Provider” means a Manager, Consultant or other individual who, in the discretion of the Board, provides
services to the Company (or indirectly through another Person, for the benefit of the Company), in such Person’s capacity as such. 

(ee) “Subsidiary” means any entity in an unbroken chain of entities beginning with the Company, if each of the entities other
than the last entity in the chain owns shares or ownership interests possessing 50% or more of the total combined voting power of all classes of shares or ownership interests in one of the other entities in such chain. 

(ff) “Trigger Event” means the consummation of the conversion of the Company or its business into a corporation. 

(gg) “Unit” means a Common Unit or share of the Company into which a Common Unit has been converted, as adjusted in
accordance with Section 13 below. 
 3. Units Subject to the Plan.
Subject to the provisions of Section 13 of the Plan, the maximum aggregate number of Units that may be subject to Awards and sold under the Plan is 10,850,000 Units. The Units may be authorized, but unissued, or reacquired Common Units. The
Company, during the term of this Plan, will at all times reserve and keep available such number of Units as will be sufficient to satisfy the requirements of the Plan. 

If an Award expires or becomes unexercisable without having been exercised in full, or is surrendered pursuant to an Exchange Program, the
unpurchased Units which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated); provided, however, that Units that have actually been issued under the Plan will not be returned to
the Plan and will not become available for future distribution under the Plan, except that if unvested Units are repurchased by the Company or are forfeited to the Company due to the failure to vest, such Units will become available for future grant
under the Plan. 

  
 -3- 

 4.
Administration of the Plan. 
 (a) Procedure. The Board or a
Committee appointed by the Board will administer the Plan. Any such Committee will be constituted to comply with Applicable Laws and the Operating Agreement. 

(b) Powers of the Administrator. Subject to the provisions of the Plan and, in
the case of a Committee, the specific duties delegated by the Board to such Committee, and subject to the Operating Agreement and the approval of any relevant authorities, the Administrator will have the authority, in its discretion: 

(i) to determine the Fair Market Value; 

(ii) to select the Service Providers and such other individuals to whom Awards may from time to time be granted hereunder; 

(iii) to determine the number of Units to be covered by each such Award granted hereunder; 

(iv) to approve forms of Award Agreement for use under the Plan; 

(v) to determine the terms and conditions of any Award granted hereunder. Such terms and conditions include, but are not limited to, the
exercise price, the time or times when Options may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Units relating
thereto, based in each case on such factors as the Administrator will determine; 
 (vi) to institute an Exchange Program; 

(vii) to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws; 
 (viii) to construe and
interpret the terms of the Plan and Awards granted under the Plan; 
 (ix) to modify or amend each Award (subject to Section 18(c) of
the Plan), including the discretionary authority to extend the post-termination exercisability period of Options and the maximum term Options (subject to Section 6(a) of the Plan); 

(x) to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Option previously granted
by the Administrator; and 
 (xi) to make all other determinations deemed necessary or advisable for administering the Plan. 

  
 -4- 

 (c) Effect of Administrator’s Decision.
All decisions, determinations and interpretations of the Administrator will be final and binding on all Participants and will be made in conformity in all respects with the Operating Agreement. 

5. Eligibility. Awards may be granted to Service Providers as the Administrator may determine. 

6. Options. 
 (a) Term
of Option. The term of each Option will be stated in the Option Agreement; provided, however, that the term will be no more than ten (10) years from the date of grant thereof. 

(b) Option Exercise Price and Consideration. 

(i) The Administrator will determine the per unit exercise price for the Units to be issued pursuant to exercise of an Option, provided,
however, that the per Unit exercise price will be no less than one hundred percent (100%) of the Fair Market Value per Unit on the date of grant. 

(ii) The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment. Such
consideration may consist entirely of: (1) cash; (2) check; (3) other Units, provided that such Units have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Units as to which such Option will be
exercised and provided further that accepting such Units will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion; (4) consideration received by the Company under cashless
exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan; (5) such other consideration and method of payment for the issuance of Units to the extent permitted by Applicable Laws, or
(6) any combination of the foregoing methods of payment. In making its determination as to the type of consideration to accept, the Administrator will consider if acceptance of such consideration may be reasonably expected to benefit the
Company. 
 (c) Exercise of Option. 

(i) Procedure for Exercise; Rights as a Member. Any Option granted hereunder will be exercisable
according to the terms of the Plan and at such times and under such conditions as determined by the Administrator and set forth in the Option Agreement. An Option may not be exercised for a fraction of a Unit. 

An Option will be deemed exercised when the Company receives: (i) written or electronic notice of exercise (in accordance with the
Option Agreement) from the person entitled to exercise the Option, and (ii) full payment for the Units with respect to which the Option is exercised (together with any applicable withholding taxes that may arise upon such exercise). Full
payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Option Agreement and the Plan. Units issued upon exercise of an Option will be issued in the name of the Participant or, if requested
by the Optionee, in the name of the Participant and his or her spouse. Until the Units are issued (as evidenced by the appropriate entry 

  
 -5- 

 
on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive allocations of profits or losses or any other rights as a Member will exist with
respect to the Units, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Units promptly after the Option is exercised. No adjustment will be made for an allocation of profit or loss or other right for
which the record date is prior to the date the Units are issued, except as provided in Section 12 of the Plan. A Participant will only be entitled to prospective allocations of profit or loss upon issuance of Units pursuant to an Option
exercise. 
 Exercise of an Option in any manner will result in a decrease in the number of Units thereafter available, both for purposes
of the Plan and for sale under the Option, by the number of Units as to which the Option is exercised. 
 (ii)
Termination of Relationship as a Service Provider. If a Participant ceases to be a Service Provider, other than upon termination as the result of the Participant’s death or Disability, such Participant may exercise his
or her Option within thirty (30) days of termination, or such longer period of time as specified in the Option Agreement, to the extent that the Option is vested on the date of termination (but in no event later than the expiration of the term
of the Option as set forth in the Option Agreement). Unless the Administrator provides otherwise, if on the date of termination the Participant is not vested as to his or her entire Option, the Units covered by the unvested portion of the Option
will revert to the Plan. If, after termination, the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Units covered by such Option will revert to the Plan. 

(iii) Disability of Participant. If a Participant ceases to be a Service Provider as a result of the Participant’s Disability,
the Participant may exercise his or her Option within six (6) months of termination, or such longer period of time as specified in the Option Agreement, to the extent the Option is vested on the date of termination (but in no event later than
the expiration of the term of such Option as set forth in the Option Agreement). Unless the Administrator provides otherwise, if on the date of termination the Participant is not vested as to his or her entire Option, the Units covered by the
unvested portion of the Option will revert to the Plan. If, after termination, the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and the Units covered by such Option will revert to the
Plan. 
 (iv) Death of Participant. If a Participant dies while a Service Provider, the Option
may be exercised within six (6) months following the Participant’s death, or such longer period of time as specified in the Option Agreement, to the extent that the Option is vested on the date of death (but in no event later than the
expiration of the term of such Option as set forth in the Option Agreement) by the Participant’s designated beneficiary, provided such beneficiary has been designated prior to the Participant’s death in a form acceptable to the
Administrator. If no such beneficiary has been designated, then such Option may be exercised by the personal representative of the Participant’s estate or by the person(s) to whom the Option is transferred pursuant to the Participant’s
will or in accordance with the laws of descent and distribution. If, at the time of death, the Participant is not vested as to his or her entire Option, the Units covered by the unvested portion of the Option will immediately revert to the Plan. If
the Option is not so exercised within the time specified herein, the Option will terminate, and the Units covered by such Option will revert to the Plan. 

  
 -6- 

 7. Profits Interests. 

(a) Profits Interest Agreement. Subject to the terms of the Plan and the Operating Agreement, the Administrator may grant Profits
Interests in such amounts as the Administrator, in its sole discretion, will determine. Each Profits Interest grant will be evidenced by a Profits Interest Agreement that will specify the number of Units that are being granted as Profits Interests,
the Profits Interest Threshold Amount, the vesting schedule, if any, applicable to the Profits Interest grant, and such other terms and conditions as the Administrator, in its sole discretion, will determine. 

(b) Forfeiture. If a Participant’s status as a Service Provider is terminated for any reason by the Participant or the Company
before the Profits Interests have vested, unless otherwise determined by the Administrator or unless otherwise provided in the Profits Interest Agreement, the Participant will forfeit all non-vested Profits
Interests to the Company for no consideration without further action by the Company. 
 (c) Rights as a Member. Each Participant
granted a Profits Interest Award shall agree to be bound by and comply with the terms of the Operating Agreement. 
 (d) Payment.
Unless otherwise determined by the Administrator, no amount shall be paid to the Company for the grant of Profits Interests. 
 8.
Restricted Common Units. 
 (a) Grant. Restricted Common Units may be granted at any time and from time to time as determined
by the Administrator. After the Administrator determines that it will grant Restricted Common Units, it will advise the Participant in a Restricted Unit Award Agreement of the terms, conditions, and restrictions related to the grant, including the
number of Restricted Common Units. 
 (b) Vesting Criteria and Other Terms. Restricted Common Units may be granted fully vested or
may be subject to vesting criteria established by the Administrator in its discretion, which, depending on the extent to which the criteria are met, will determine the number of Restricted Common Units that will be paid out to the Participant. The
Administrator may set vesting criteria based upon the achievement of Company-wide, business unit, or individual goals (including, but not limited to, continued employment or service), or any other basis determined by the Administrator in its
discretion. 
 (c) Earning Restricted Common Units. Upon meeting the applicable vesting criteria, the Participant will be entitled to
receive a payout as determined by the Administrator. Notwithstanding the foregoing, at any time after the grant of Restricted Common Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to
receive a payout. 
 (d) Form and Timing of Payment. Payment of earned Restricted Common Units will be made as soon as practicable
after the date(s) determined by the Administrator and set forth in the Award Agreement. Restricted Common Units will be settled through the issuance of Units. 

  
 -7- 

 (e) Cancellation. On the date set forth in the Award Agreement, all unearned
Restricted Common Units will be forfeited to the Company. 
 9. Compliance With Code Section 409A. Awards will be
designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Code Section 409A, except as otherwise determined in the sole discretion of the Administrator. The Plan and each
Award Agreement under the Plan is intended to meet the requirements of Code Section 409A and will be construed and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator. To
the extent that an Award or payment, or the settlement or deferral thereof, is subject to Code Section 409A, the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Code Section 409A, such
that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section 409A. 

10. Leaves of Absence/Transfer Between Locations. Unless the Administrator provides otherwise, vesting of Awards granted hereunder will
be suspended during any unpaid leave of absence. A Service Provider will not terminate service in the case of (i) any leave of absence approved by the Company or (ii) transfers between locations of the Company or between the Company, its
Parent, or any Subsidiary. 
 11. Limited Transferability of Awards. Unless determined
otherwise by the Administrator, Awards may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or the laws of descent and distribution, and may be exercised during the lifetime of the
Participant, only by the Participant. If the Administrator in its sole discretion makes an Award transferable, such Award may only be transferred (i) by will, (ii) by the laws of descent and distribution, or (iii) as permitted by Rule
701 of the Securities Act. 
 12. Trigger Event. Subject to the provisions of the merger, reorganization or other agreement setting
forth the terms of a direct exchange, merger or other reorganization transaction, upon a Trigger Event, all Awards granted under the Plan will be exchanged for or converted into, in such transaction, options to acquire shares of the resulting
corporation’s common stock of which the base amount on which compensation is measured is determined by reference to the value of the resulting corporation’s common stock with terms substantially equivalent to the terms of the options, as
the case may be, they are intended to replace. 
 13. Adjustments; Liquidity Event. 

(a) Adjustments. Subject to any required action by the Members of the Company, in the event of any split, reverse split, dividend,
recapitalization, combination, reclassification, reorganization, merger, consolidation, split-up, spin-off, repurchase, exchange of Units or other securities of the
Company, other distribution of Units or other securities of the Company without the receipt of consideration by the Company, or other change in the corporate structure of the Company affecting the Units occurs, the Administrator, in order to prevent
diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and class of Units that may be delivered under the Plan and/or the number, class, and price of Units covered by each
outstanding Award; provided, however, that the Administrator will make adjustments to an Award required by Section 25102(o) of the California Corporations Code to the extent the Company is relying upon the exemption afforded thereby with
respect to an Award. 

  
 -8- 

 (b) Merger or Liquidation Event. In the event that the Company is subject to a merger
or Liquidation Event, outstanding Awards shall be subject to the agreement governing the merger or Liquidation Event and the Operating Agreement. The agreement governing the merger or Liquidity Event shall provide for one or more of the following:

 (c) The continuation of such outstanding Awards by the Company (if the Company is the surviving corporation). 

(d) The assumption, or substitution of substantially equivalent Awards, by the acquiring or succeeding corporation (or an affiliate thereof)
with appropriate adjustments to the number and kind of equity interests and prices, with appropriate reduction to the Common Unit exchange ratio applicable to Profits Interests to reflect the applicable Profits Interest Threshold Amounts. 

(e) The full or partial vesting of unvested Awards, or the full or partial cancellation of unvested Awards without consideration, in each case
upon on the closing of the merger or Liquidation Event. 
 (f) The cancellation or redemption of outstanding Awards in exchange for a
payment, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Participant rights as of the date of the occurrence of the transaction. Such payment may be made in the form of cash, cash
equivalents, or securities of the surviving entity or its parent with a fair market value equal to the amount distributable or deemed distributable in the merger or Liquidity Event. Such payment may be subject to vesting based on the
Participant’s continuing service, provided that the vesting schedule shall not be less favorable to the Participant than the schedule under which such Award would have vested. If no amounts would be distributable to such Award holder and/or if
such Award is unvested, then such Award may be cancelled without making a payment to the Participant. 
 (g) Amounts of cash or other
consideration from a sale of assets of the Company or a Subsidiary constituting a Liquidity Event otherwise distributable to a Common Unit holder shall be reduced by the Profits Interest Threshold Amount attributable to each such Profits Interest
receiving such distribution. 
 14. Tax Withholding. 

(a) Withholding Requirements. Prior to the delivery of any Units or cash pursuant to an Award (or exercise thereof), the Company will
have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including the Participant’s FICA obligation) required to be
withheld with respect to such Award (or exercise thereof). 
 (b) Withholding Arrangements. The Administrator, in its sole discretion
and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (i) paying cash,

  
 -9- 

 
(ii) electing to have the Company withhold otherwise deliverable Units having a Fair Market Value equal to the minimum statutory amount required to be withheld, (iii) delivering to the
Company already-owned Units having a Fair Market Value equal to the statutory amount required to be withheld, provided the delivery of such Units will not result in any adverse accounting consequences, as the Administrator determines in its sole
discretion, or (iv) selling a sufficient number of Units otherwise deliverable to the Participant through such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required
to be withheld. The amount of the withholding requirement will be deemed to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state
or local marginal income tax rates applicable to the Participant with respect to the Award on the date that the amount of tax to be withheld is to be determined. The Fair Market Value of the Units to be withheld or delivered will be determined as of
the date that the taxes are required to be withheld. 
 15. No Effect on Employment or Service. Neither the Plan nor any Award will
confer upon a Participant any right with respect to continuing the Participant’s relationship as a Service Provider, nor interfere in any way with the Participant’s or the Company’s right to terminate such relationship at any time,
with or without cause, to the extent permitted by Applicable Laws. 
 16. Date of Grant. The date of grant of an Award will, for all
purposes, be the date on which the Administrator makes the determination granting such Award, or such later date as the Administrator may determine. Notice of the determination will be provided to each Service Provider to whom an Award is so granted
within a reasonable time after the date of such grant. 
 17. Term of Plan. The Plan will
become effective upon its adoption by the Board. Unless sooner terminated under Section 18, it will continue in effect for a term of ten (10) years from the later of (a) the effective date of the Plan, or (b) the earlier of the
most recent Board or Member approval of an increase in the number of Units reserved for issuance under the Plan. 
 18.
Amendment and Termination of the Plan. 

(a) Amendment and Termination. The Administrator may at any time amend, alter, suspend or terminate the Plan. 

(b) Member Approval. The Company will obtain Member approval of any Plan amendment to the extent necessary and desirable to comply with
the Operating Agreement and Applicable Laws. 
 (c)
Effect of Amendment or Termination. No amendment, alteration, suspension or termination of the Plan will impair the rights of any Participant, unless mutually agreed
otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company. Termination of the Plan will not affect the Administrator’s ability to exercise the powers granted to it
hereunder with respect to Awards granted under the Plan prior to the date of such termination. 

  
 -10- 

 19.
Conditions Upon Issuance of Units.  
 (a)
Legal Compliance. Units will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Units will comply with Applicable Laws and will be further subject to the approval of
counsel for the Company with respect to such compliance. 
 (b) Investment Representations. As a condition to the exercise of an
Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Units are being purchased only for investment and without any present intention to sell or distribute such Units if,
in the opinion of counsel for the Company, such a representation is required. 
 20. Inability to Obtain Authority. The inability of
the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Units hereunder, will relieve the Company of any liability
in respect of the failure to issue or sell such Units as to which such requisite authority will not have been obtained. 
 21. Member
Approval. The Plan will be subject to approval by the Members of the Company within twelve (12) months after the date the Plan is adopted by the Board. Such Member approval will be obtained in the manner and to the degree required under
Applicable Laws. 

  
 -11-EX-10.9

 Exhibit 10.9 

 
 EXCLUSIVE LICENSE AGREEMENT 

between 
 InCube Labs, LLC.
(“Licensor”) 
 and 

Rani Therapeutics, LLC (“Licensee”) 
  

 EXCLUSIVE LICENSE AGREEMENT 

This exclusive license agreement (the “Agreement”) is made effective on June 14, 2012 (the “Effective Date”), between
InCube Labs, LLC (“Licensor”), and Rani Therapeutics, LLC, a California limited liability corporation (“Licensee”). 

BACKGROUND 
 A. Certain
inventions, generally relating to the Field of Use are covered by Licensor’s Patent Rights as defined below. 
 B. Licensee wishes to
obtain the rights from Licensor for the exclusive commercial development, use and sale of Licensed Products and Services from the Invention, and Licensor is willing to grant those rights. 

C. Licensor reserves the right to grant additional licenses outside the Field of Use. 

In view of the foregoing, the parties, recognizing the receipt and sufficiency of consideration herein, agree: 

1. DEFINITIONS 
 1.1 “Field of Use”
means “ORAL DELIVERY OF BIOTHERAPEUTIC AGENTS SUCH AS PEPTIDES, PROTEINS & ANTIBODIES” but excludes “SWALLOWABLE DEVICES THAT DO NOT DELIVER SUCH DRUGS”. 

1.2 “Licensed Products and Services” means any services, compositions or products the manufacture, use, sale, offer for sale,
importation or practice of which would constitute, but for the license granted Licensee by Licensor herein, an infringement of any pending or issued valid and unexpired claim within Licensor’s Patent Rights. 

1.3 “Licensor’s Patent Rights” means Licensor’s interest in the patents and patent applications listed on Exhibit A,
together with continuations, divisionals, substitutions and continuation-in-part applications (but in the case of continuations-in-part only to the extent that claims are supported in the applications listed on Exhibit A or any patent application from which the same derive); and patents issuing on said applications
including registrations, reissues, reexaminations and extensions and the corresponding foreign applications and patents. 
 1.4
“Sublicensee” means a third party to whom Licensee grants a sublicense under this Agreement. 
 2. LIFE OF PATENT EXCLUSIVE GRANT 

2.1 Subject to the limitations set forth in this Agreement, Licensor grants to Licensee an exclusive paid up royalty free license under
Licensor’s Patent Rights to make, have made, use, offer to sell, sell and import Licensed Products and Services to the extent permitted by applicable law. The license granted in Paragraph 2.1 is exclusive for the term of this Agreement. 

2.2 The license granted in Paragraph 2.1 is limited to products and services that are within the Field of Use. For all other products and
services, Licensee has no license under this Agreement. 

  
 1 

CONFIDENTIAL 

 3. SUBLICENSES 

3.1 Licensor also grants to Licensee the right to grant and authorize sublicenses to third parties to make, have made, use, offer to sell, sell
and import Licensed Products and Services, as long as Licensee has current exclusive rights thereto under this Agreement. To the extent applicable, sublicenses must include all of the rights of and obligations due to Licensor (and, if applicable,
the U.S. Government) contained in this Agreement. 
 3.2 Licensee shall promptly provide Licensor with a copy of each sublicense issued
(which copy may be redacted with respect to information not pertinent to compliance with the terms and conditions of this Agreement) 
 3.3
Upon termination of this Agreement for any reason, all sublicenses shall survive such termination, provided that, upon request by Licensor, the applicable Sublicensee agrees in writing to be bound by the applicable terms of this Agreement. 

4. DUE DILIGENCE 
 4.1 Licensee, upon execution
of this Agreement, shall diligently proceed with the development, manufacture and sale of Licensed Products and Services and shall earnestly and diligently endeavor to market the same within a reasonable time after execution of this Agreement and in
quantities sufficient to meet market demands. 
 4.2 Licensee shall endeavor to obtain all necessary governmental approvals for the
manufacture, use and sale of Licensed Products and Services. 
 5. PROGRESS REPORTS 

5.1 Beginning with the Effective Date and annually thereafter, Licensee shall submit to Licensor a written progress report covering
Licensee’s (and any Affiliate’s or Sublicensee’s) activities related to the development and testing of all Licensed Products and Services and the obtaining of the governmental approvals necessary for marketing. 

6. TERM OF THE AGREEMENT 
 6.1 Unless otherwise
terminated by operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement will be in force from the Effective Date until the later of (i) the date of expiration of the
last-to-expire patent licensed under this Agreement or (ii) the date that the last patent application licensed under this Agreement is abandoned. 

6.2 Upon the sale or merger of the Licensee, the obligations of the Licensor to license additional patents to Licensee shall cease as of the
effective date of the sale or merger. All other terms of this license agreement pertaining to patents or patent applications that have already been licensed under this agreement shall continue. 

6.3 Licensee has the right at any time to terminate this Agreement in whole or as to any portion of Licensor’s Patent Rights by giving
notice in writing to Licensor. Such notice of termination will be subject to Article 14 (Notices) and termination of this Agreement will be effective 60 days from the effective date of such notice. In the event of termination by the Licensee, all
rights so terminated shall revert back to the Licensor. 

  
 2 

 6.4 Any termination under the above paragraph does not relieve Licensee of any obligation or
liability accrued under this Agreement prior to termination or rescind any payment made to Licensor or anything done by Licensee prior to the time termination becomes effective. Termination does not affect in any manner any rights of Licensor
arising under this Agreement prior to termination. 
 7. USE OF NAMES AND TRADEMARKS 

7.1 Nothing contained in this Agreement confers any right to use in advertising, publicity or other promotional activities any name, trade
name, trademark or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). 
 8. LIMITED
WARRANTIES AND LIMITATIONS ON LIABILITY 
 8.1 Licensor represents and warrants to Licensee that: (i) it has the lawful right to enter
into this Agreement and grant the rights and licenses hereunder, (ii) Licensor is and shall be the owner of the entire right, title, and interest in and to Licensor’s Patent Rights, (iii) Licensor has not previously granted and will
not grant any rights in Licensor’s Patent Rights that are inconsistent with the rights and licenses granted to Licensee herein, (iv) to Licensor’s knowledge, there are no claims of any third parties that would call into question the
rights of Licensor to grant to Licensee the rights and licenses granted hereunder, (v) to Licensor’s knowledge, practice of Licensor’s Patent Rights will not infringe intellectual property rights of third parties and (vi) except
for Licensor’s Patent Rights, and the inventions disclosed therein, as of the Effective Date, Licensor does not own or control rights to any patent, patent application or invention pertaining to the Invention or the claims of which would
dominate any practice of Licensor’s Patent Rights. 
 8.2 This Agreement does not: 

8.2.1 express or imply a warranty or representation as to the validity or scope of any of Licensor’s Patent Rights; 

8.2.2 express or imply a warranty or representation that anything made, used, sold, offered for sale or imported or otherwise disposed of
under any license granted in this Agreement is or will be free from infringement of patents of third parties; 
 8.2.3 obligate Licensor to
bring or prosecute actions or suits against third parties for patent infringement except as provided in Article 11 (Patent Infringement); 

8.2.4 confer by implication, estoppel or otherwise any license or rights under any patents of Licensor other than Licensor’s Patent
Rights as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Licensor’s Patent Rights; or 

8.2.5 obligate Licensor to furnish any know-how not provided in Licensor’s Patent Rights. 

8.3 LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY SPECIAL OR INCIDENTAL DAMAGES, HOWEVER CAUSED AND ON ANY
THEORY OF LIABILITY ARISING OUT OF THIS AGREEMENT, AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE AGGREGATE LIABILITY OF EACH PARTY UNDER THIS AGREEMENT SHALL NOT EXCEED AMOUNTS PAYABLE OR PAID UNDER THIS
AGREEMENT. THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN. THE ABOVE LIMITATIONS OF LIABILITY SHALL NOT APPLY TO ANY LIABILITY ARISING OUT OF INDEMNIFICATION OR CONFIDENTIALITY
OBLIGATIONS. 

  
 3 

 8.4 DISCLAIMER OF WARRANTIES. EXCEPT AS EXPRESSY SET FORTH HEREIN, EACH PARTY
DISCLAIMS ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY AND ALL IMPLIED WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT. 

9. PATENT PROSECUTION AND MAINTENANCE 
 9.1 As
long as Licensee has paid patent costs as provided for in this Article 15 (Patent Prosecution and Maintenance), Licensor shall diligently endeavor to prosecute and maintain the U.S. and foreign patent applications and patents comprising
Licensor’s Patent Rights using counsel of its choice, and Licensor shall provide Licensee with copies of all relevant documentation so that Licensee may be informed of the continuing prosecution, and Licensee agrees to keep this documentation
confidential. Licensor’s counsel will take instructions only from Licensor, and all patents and patent applications under this Agreement will be assigned solely to Licensor. 

9.2 Licensor shall use reasonable efforts to amend any patent application to include claims and take such other actions with respect to the
filing, prosecution and maintenance of the Licensor’s Patent Rights reasonably requested by Licensee to protect the products and services contemplated to be sold under this Agreement. Licensee to pay cost for such actions requested by Licensee.

 9.3 If requested by Licensor, Licensee shall apply for an extension of the term of any patent included within Licensor’s Patent
Rights if appropriate under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this Law. Licensee shall prepare all documents and Licensor agrees to execute the documents
and to take additional action as Licensee reasonably requests in connection therewith. 
 9.4 If either party receives notice pertaining to
infringement or potential infringement of any issued patent included within Licensor’s Patent Rights under the Drug Price Competition and Patent Term Restoration Act of 1984 (and/or foreign counterparts of this law), then that party shall
notify the other party within 10 days after receipt of notice of infringement. 
 9.5 Licensee may request Licensor to obtain patent
protection on the Invention in foreign countries if available and if it so desires. Licensee shall notify Licensor of its decision to obtain or maintain foreign patents not less than 60 days prior to the deadline for any payment, filing or action to
be taken in connection therewith. This notice concerning foreign filing must be in writing, must identify the countries desired and must reaffirm Licensee’s obligation to underwrite the costs thereof. The absence of such a notice from Licensee
to Licensor will be considered an election not to obtain or maintain foreign rights. 
 9.6 Licensor may file, prosecute or maintain patent
applications at its own expense in any country in which Licensee has not elected to file, prosecute or maintain patent applications in accordance with this Article 9 (Patent Prosecution and Maintenance) and those applications and resultant patents
will not be subject to this Agreement. 
 9.7 Licensee shall promptly pay the Licensor the prorata portion with other licensees, all
expenses that the Licensor incurs for the prosecution and maintenance of Licensed Patents (this may include PTO fees, outside attorneys, PTO travel, foreign filing costs). Licensor shall bill these expenses as incurred. 

  
 4 

 10. PATENT MARKING 

Licensee shall mark all Licensed Products and Services made, used or sold under the terms of this Agreement, or their containers, in accordance
with the applicable patent marking laws. 
 11. PATENT INFRINGEMENT 

11.1 If either party learns of the substantial infringement of any patent licensed under this Agreement, then such party shall call the other
party’s attention thereto in writing and provide such other party with reasonable evidence of infringement. Neither party will notify a third party of the infringement of any of Licensor’s Patent Rights without first obtaining consent of
the other party, which consent will not be unreasonably denied, conditioned or delayed. Both parties shall use their commercially reasonable efforts in cooperation with each other to terminate infringement without litigation. 

11.2 Licensee may request that Licensor take legal action against the infringement of Licensor’s Patent Rights. Such request must be in
writing and must include reasonable evidence of infringement and damages to Licensee. If the infringing activity has not abated within 90 days following the effective date of request, then Licensor has the right to: 

11.2.1 commence suit on its own account; or 

11.2.2 refuse to commence suit, in which case Licensor shall give notice of its election in writing to Licensee by the end of the 100th day
after receiving notice of written request from Licensee. Licensee may thereafter bring suit for patent infringement, at its own expense, if and only if, Licensor elects not to commence suit and if the infringement occurred during the period and in a
jurisdiction where Licensee had exclusive rights under this Agreement. If Licensee elects to bring suit in accordance with this Paragraph 11.2, then Licensor may thereafter at its option join that suit at its own expense. However, if licensor does
not voluntarily join the suit, Licensor agrees to be joined as a party to the suit at the request of the licensee. In such an event, licensee will pay the costs involved in joining the Licensor to the suit. Each party agrees not to bring suit for
patent infringement without following the procedures of this Paragraph 11.2, and both parties agree to be bound by an order of a court for patent infringement, patent infringement issues and patent infringement defenses as determined through such a
suit under this Paragraph 11.2. 
 11.3 If Licensor elects not to commence suit, legal action will be at Licensee’s expense and
Licensee shall retain all damages recovered thereby. Otherwise, legal action brought by Licensor and fully participated in by both parties will be at the joint and equal expense of the parties and all recoveries from such a suit will first be
applied to the litigation costs and fees of the parties bringing suit. 
 11.4 Each party shall cooperate with the other in litigation
proceedings instituted hereunder but at the expense of the party bringing suit. Litigation will be controlled by the party bringing the suit, except that Licensor may be represented by counsel of its choice in any suit brought by Licensee. 

12. INDEMNIFICATION 
 12.1 Licensee shall
indemnify, hold harmless and defend Licensor, its officers, employees and agents against any and all claims, suits, losses, liabilities, damages, costs, fees and expenses resulting from product liability arising out of exercise of this license or
any sublicense, provided, however, that the indemnified party (i) promptly notifies Licensee of the applicable claim, (ii) gives Licensee sole control of the defense or settlement of such claim and (iii) provides Licensee, at its
expense, with reasonable assistance and full information with respect to such claim. Notwithstanding the foregoing, Licensee shall have no obligations for any claim if the indemnified party makes any admission, settlement or other communication
regarding such claim without the prior written consent of Licensee, which consent shall not be unreasonably withheld. 

  
 5 

 12.2 Licensee, at its sole cost and expense, shall insure its activities in connection with
the work under this Agreement and obtain, keep in force and maintain insurance as set forth in Paragraph 18.3 or an equivalent program of self-insurance. 

12.3 Comprehensive or commercial form general liability insurance (contractual liability included), commencing prior to trials involving
humans, with limits as follows: 
  

	 	•	 	 Each Occurrence $1,000,000 

 

	 	•	 	 Products/Completed Operations Aggregate $5,000,000 

 

	 	•	 	 Personal and Advertising Injury $1,000,000 

 

	 	•	 	 General Aggregate (commercial form only) $5,000,000 

The coverage and limits referred to under the above do not in any way limit the liability of Licensee. Licensee shall furnish Licensor with
certificates of insurance showing compliance with all requirements. Certificates must: 
  

	 	•	 	 Provide for 30 day advance written notice to Licensor of any modification. 

 

	 	•	 	 Indicate that Licensor has been endorsed as an additional insured under the coverage referred to above.

  

	 	•	 	 Include a provision that the coverage will be primary and will not participate with nor will be excess over any
valid and collectable insurance or program of self insurance carried or maintained by Licensor. 

 12.4 Licensor shall
notify Licensee in writing of any claim or suit brought against Licensor in respect of which Licensor intends to invoke the provisions of this Article 12 (Indemnification). Licensee shall keep Licensor informed on a current basis of its defense of
any claims under this Article 18 (Indemnification). 
 13. CONFIDENTIALITY 

13.1 Except as otherwise provided herein, each party shall maintain in confidence, and shall not use for any purpose or disclose to any third
party information disclosed by the other party in writing and marked “Confidential” or that is disclosed orally and confirmed in writing as confidential within 45 days following such disclosure (collectively, “Confidential
Information”). Confidential Information shall not include any information that is: (i) already known to the receiving party at the time of disclosure hereunder, or (ii) now or hereafter becomes publicly known other than through acts
or omissions of the receiving party, or (iii) disclosed to the receiving party by a third party under no obligation of confidentiality to the disclosing party or (iv) independently developed by the receiving party without reference to the
Confidential Information of the disclosing party. 
 13.2 Notwithstanding the provisions of Paragraph 13.1 above, each party may use or
disclose Confidential Information in exercising its rights hereunder or fulfilling its obligations and duties hereunder and in prosecuting or maintaining any proprietary rights, prosecuting or defending litigation, complying with applicable
governmental regulations and submitting information to tax or other governmental authorities, provided that if the party is required by law to make any public disclosures of Confidential Information of the other, to the extent it may legally do so,
the party will give reasonable advance notice to the other of such disclosure and will use its reasonable efforts to secure confidential treatment of Confidential Information prior to its disclosure (whether through protective orders or otherwise).

  
 6 

 14. NOTICES 

14.1 Any notice or payment required to be given to either party shall be deemed to have been properly given and to be effective as of the date
specified below if delivered to the respective address or facsimile number given below or to another address or facsimile number as designated by written notice given to the other party: 

14.1.1 on the date of delivery if delivered in person; 

14.1.2 on the date of mailing if mailed by first-class certified mail, postage paid; 

14.1.3 on the date of mailing if mailed by any global express courier service that requires recipient to sign the documents demonstrating the
delivery of such notice or payment; or 
 14.1.4 on the date of transmission if sent by facsimile with confirmation of transmission. 

 

					
		 	In the case of Licensee:	 	Rani Therapeutics, LLC
		 		 	2051 Ringwood Avenue
		 		 	San Jose, Ca 95131
			
		 	In the case of Licensor:	 	InCube Labs, LLC
		 		 	2051 Ringwood Avenue
		 		 	San Jose, Ca 95131

 15. ASSIGNABILITY. 

Each party may assign this agreement in whole or in part to a party succeeding to substantially all of the assigning party’s assets
relating to this Agreement. Upon a permitted assignment of this Agreement by a party, all references herein to such party shall be deemed a reference to the assignee. Any other attempt to transfer or assign shall be void without the prior written
consent of the other party. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of each party and their respective successors and authorized assigns. 

16. NO WAIVER. 
 No waiver by either party of any
default of this Agreement may be deemed a waiver of any subsequent or similar default. A suspension of duty under this Agreement due to force majeure shall not be for a period longer than 1 year. 

17. FAILURE TO PERFORM. 
 Subject to Article 20,
if either party finds it necessary to undertake legal action against the other on account of failure of performance due under this Agreement, then the prevailing party is entitled to reasonable attorney’s fees in addition to costs and necessary
disbursements. 
 18. GOVERNING LAWS. 
 THIS
AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA WITHOUT REGARD TO CONFLICT OF 

  
 7 

 
LAWS OR TO WHICH PARTY DRAFTED PARTICULAR PROVISIONS OF THIS AGREEMENT, but the scope and validity of any patent or patent application will be governed by the applicable laws of the country of
the patent or patent application. Disputes between the parties regarding this Agreement will utilize only trial courts within California for disputes that go to court. 

19. EXPORT CONTROL LAWS. 
 Licensee shall observe
all applicable U.S. and foreign laws with respect to the transfer of Licensed Products and Services and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export
Administration Regulations. 
 20. DISPUTE RESOLUTION 

Both parties shall undertake all reasonable best efforts to resolve in an amicable manner any dispute arising in connection with this
Agreement. Any dispute arising between the parties in connection with this Agreement which cannot be resolved through good faith negotiation shall be referred to binding arbitration in San Jose, California, U.S.A. to be conducted by the Judicial
Arbitration and Mediation Services, Inc. (or any successor entity thereto) (“JAMS”) under its rules of arbitration then in effect, except as modified in this Agreement. The arbitration shall be conducted by a single arbitrator. The
arbitrator shall engage an independent expert with experience in the subject matter of the dispute to advise the arbitrator. If the parties are unable to agree upon an arbitrator, one shall be chosen by JAMS. The decision of the arbitrator,
including any award, shall be final and binding upon the parties. Any decision of the arbitrator may be entered in a court of competent jurisdiction for judicial recognition of the decision and an order of enforcement. The arbitration proceedings
and the decision of the arbitrator shall not be made public without the written consent of both parties, and each party shall maintain the confidentiality of such proceedings and decision, unless otherwise agreed in writing by the parties. The
parties agree that they shall share equally the cost of the arbitration filing and hearing fees, the cost of the independent expert retained by the arbitrator and the cost of the arbitrator and administrative fees of JAMS. Each party shall bear its
own costs and attorneys’ and witnesses’ fees and associated costs and expenses. Pending the selection of the arbitrator or pending the arbitrator’s determination of the merits of any dispute, either party may seek appropriate interim
or provisional relief from any court of competent jurisdiction as necessary to protect the rights or property of that party. Notwithstanding the foregoing, any dispute or controversy relating to the inventorship and ownership of any invention or the
scope, validity, enforceability or infringement of any intellectual property rights shall be submitted to a court of competent jurisdiction in the territory in which such intellectual property rights were granted or arose. 

21. MISCELLANEOUS 
 21.1 The headings of the
several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

21.2 This Agreement is not binding on the parties until it has been signed below on behalf of each party. It is then effective as of the
Effective Date. 
 21.3 No amendment or modification of this Agreement is valid or binding on the parties unless made in writing and signed
on behalf of each party. 
 21.4 This Agreement embodies the entire understanding of the parties and supersedes all previous communications,
representations or understandings, either oral or written, between the parties relating to the subject matter hereof. 

  
 8 

 21.5 In case any of the provisions contained in this Agreement is held to be invalid,
illegal or unenforceable in any respect, that invalidity, illegality or unenforceability will not affect any other provisions of this Agreement and this Agreement will be construed as if the invalid, illegal or unenforceable provisions had never
been contained in it. 
 21.6 None of the provisions of this Agreement is intended to create any form of joint venture between the parties,
rights in third parties or rights that are enforceable by any third ply. 
 21.7 Notwithstanding the foregoing, the Licensee agrees and
acknowledges that the Licensor is subject to preexisting obligations with respect to the development, assignment and confidentiality of intellectual property that is developed, in whole or in part, by Mir Imran or by InCube Labs, LLC, or with the
use of funds contributed by InCube Labs, LLC. Licensee agrees that its rights to any such information as provided for hereunder are in all cases subject to and limited by licensor’s preexisting rights, and that in the event of any conflict
between such preexisting rights and the rights of the licensee set forth hereunder, the preexisting rights shall prevail. 

  
 9 

 In witness whereof, both Licensor and Licensee have executed this Agreement by their
respective and duly authorized officers on the day and year written. 
  

			
	 LICENSOR
	  	LICENSEE
		
	 InCube Labs, LLC
	  	Rani Therapeutics, LLC
		
	 By: /s/ Mir
Imran                                       
                             
	  	By: /s/ Mir
Imran                                       
                             
		
	 Name: Mir
Imran                                        
                            
	  	Name: Mir
Imran                                        
                            
		
	 Title:
Chairman                                       
                               
	  	Title:
President                                       
                                 
		
	 Date: June 14,
2012                                         
                       
	  	Date: June 14,
2012                                         
                        

  
 10 

 EXHIBIT A 

LICENSOR’S PATENT RIGHTS 

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]